SARS-CoV-2 infections among Australian passengers on the Diamond Princess cruise ship: A retrospective cohort study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
02
2021
accepted:
16
07
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Prolonged periods of confined living on a cruise ship increase the risk for respiratory disease transmission. We describe the epidemiology and clinical characteristics of a SARS-CoV-2 outbreak in Australian passengers on the Diamond Princess cruise ship and provide recommendations to mitigate future cruise ship outbreaks. We conducted a retrospective cohort study of Australian passengers who travelled on the Diamond Princess from 20 January until 4 February 2020 and were either hospitalised, remained in Japan or repatriated. The main outcome measures included an epidemic curve, demographics, symptoms, clinical and radiological signs, risk factors and length of time to clear infection. Among 223 Australian passengers, 56 were confirmed SARS-CoV-2 positive. Forty-nine cases had data available and of these over 70% had symptoms consistent with COVID-19. Of symptomatic cases, 17% showed signs and symptoms before the ship implemented quarantine and a further two-thirds had symptoms within one incubation period of quarantine commencing. Prior to ship-based quarantine, exposure to a close contact or cabin mate later confirmed SARS-CoV-2 positive was associated with a 3.78 fold (95% CI, 2.24-6.37) higher risk of COVID-19 acquisition compared to non-exposed passengers. Exposure to a positive cabin mate during the ship's quarantine carried a relative risk of 6.18 (95% CI, 1.96-19.46) of developing COVID-19. Persistently asymptomatic cases represented 29% of total cases. The median time to the first of two consecutive negative PCR-based SARS-CoV-2 assays was 13 days for asymptomatic cases and 19 days for symptomatic cases (p = 0.002). Ship based quarantine was effective at reducing transmission of SARS-CoV-2 amongst Australian passengers, but the risk of infection was higher if an individual shared a cabin or was a close contact of a confirmed case. Managing COVID-19 in cruise ship passengers is challenging and requires enhanced health measures and access to onshore quarantine and isolation facilities.
Sections du résumé
BACKGROUND
Prolonged periods of confined living on a cruise ship increase the risk for respiratory disease transmission. We describe the epidemiology and clinical characteristics of a SARS-CoV-2 outbreak in Australian passengers on the Diamond Princess cruise ship and provide recommendations to mitigate future cruise ship outbreaks.
METHODS
We conducted a retrospective cohort study of Australian passengers who travelled on the Diamond Princess from 20 January until 4 February 2020 and were either hospitalised, remained in Japan or repatriated. The main outcome measures included an epidemic curve, demographics, symptoms, clinical and radiological signs, risk factors and length of time to clear infection.
RESULTS
Among 223 Australian passengers, 56 were confirmed SARS-CoV-2 positive. Forty-nine cases had data available and of these over 70% had symptoms consistent with COVID-19. Of symptomatic cases, 17% showed signs and symptoms before the ship implemented quarantine and a further two-thirds had symptoms within one incubation period of quarantine commencing. Prior to ship-based quarantine, exposure to a close contact or cabin mate later confirmed SARS-CoV-2 positive was associated with a 3.78 fold (95% CI, 2.24-6.37) higher risk of COVID-19 acquisition compared to non-exposed passengers. Exposure to a positive cabin mate during the ship's quarantine carried a relative risk of 6.18 (95% CI, 1.96-19.46) of developing COVID-19. Persistently asymptomatic cases represented 29% of total cases. The median time to the first of two consecutive negative PCR-based SARS-CoV-2 assays was 13 days for asymptomatic cases and 19 days for symptomatic cases (p = 0.002).
CONCLUSION
Ship based quarantine was effective at reducing transmission of SARS-CoV-2 amongst Australian passengers, but the risk of infection was higher if an individual shared a cabin or was a close contact of a confirmed case. Managing COVID-19 in cruise ship passengers is challenging and requires enhanced health measures and access to onshore quarantine and isolation facilities.
Identifiants
pubmed: 34492022
doi: 10.1371/journal.pone.0255401
pii: PONE-D-20-38119
pmc: PMC8423262
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0255401Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Infect Dis. 2020 Sep 1;222(7):1098-1102
pubmed: 32691828
Lancet Infect Dis. 2020 Sep;20(9):1051-1060
pubmed: 32539986
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):312-313
pubmed: 32191689
N Engl J Med. 2020 Aug 27;383(9):885-886
pubmed: 32530584
J Travel Med. 2020 Aug 20;27(5):
pubmed: 32396628
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
JAMA Netw Open. 2020 May 1;3(5):e2010182
pubmed: 32459353
Int Marit Health. 2020;71(1):5-8
pubmed: 32212140
Clin Infect Dis. 2021 May 18;72(10):e448-e457
pubmed: 32785683
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):377-381
pubmed: 32240128
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
Infect Dis Model. 2020 Feb 29;5:264-270
pubmed: 32190785
Euro Surveill. 2020 Jun;25(23):
pubmed: 32553062
J Infect. 2020 Jul;81(1):e102-e103
pubmed: 32335174
J Clin Med. 2020 Feb 29;9(3):
pubmed: 32121356
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):347-352
pubmed: 32214086
Lancet Infect Dis. 2020 Sep;20(9):1043-1050
pubmed: 32539988
Glob Health Med. 2020 Apr 30;2(2):102-106
pubmed: 33330785
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
J Travel Med. 2020 May 18;27(3):
pubmed: 32109273
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
J Infect Chemother. 2020 Aug;26(8):865-869
pubmed: 32405245